Bivariate relationship between characteristics of persons receiving concurrent TB/HIV treatment in selected THAT’SIT clinics and adherence to treatment (N = 1,252).

<p>BMI = body mass index; TB = tuberculosis; HRZE = isoniazid, rifampin, pyrazinamide, ethambutol; HRZES = isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin; DOT = directly observed therapy; WHO = World Health Organization; HIV = human immunodeficiency virus; ARV = antiretroviral; D4T/3TC/EFV = stavudine, lamivudine, efavirenz; D4T/3TC/NVP = stavudine, lamivudine, nevirapine.</p

Demographic, clinical, and social characteristics of patients receiving concurrent TB/HIV treatment in selected THAT’SIT clinics, South Africa, 2008–2010 (N = 1,252).

<p>BMI = body mass index; TB = tuberculosis; IRZE = isoniazid, rifampin, pyrazinamide, ethambutol; DOT = directly observed therapy; WHO = World Health Organization; HIV = human immunodeficiency virus; ARV = antiretroviral; D4T/3TC/EFV = stavudine, lamivudine, efavirenz; D4T/3TC/NVP = stavudine, lamivudine, nevirapine.</p

Study Population Included in TB/HIV Concurrent Treatment Analysis, 2008–2010.

<p>Study Population Included in TB/HIV Concurrent Treatment Analysis, 2008–2010.</p

Multivariate analysis of the relationship between characteristics of persons receiving concurrent TB/HIV treatment in selected THAT’SIT clinics and non-adherence to concurrent TB and HIV treatment (N = 1252).

<p>TB = tuberculosis, HIV = human immunodeficiency virus.</p

Additional file 2: of Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine — Kenya, 2009–2010

2010 survey questionnaire. (DOC 81 kb